Total Payments
$123,347
2024 Payments
$1,076
Companies
13
Transactions
101
Medicare Patients
633
Medicare Billing
$157,591
Payment Breakdown by Category
Consulting$113,621 (92.1%)
Travel$5,592 (4.5%)
Food & Beverage$3,135 (2.5%)
Other$1,000.00 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $113,621 | 36 | 92.1% |
| Travel and Lodging | $5,592 | 24 | 4.5% |
| Food and Beverage | $3,135 | 40 | 2.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,000 | 1 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $59,112 | 43 | $0 (2024) |
| SECURA BIO, INC. | $26,565 | 6 | $0 (2022) |
| Kite Pharma, Inc. | $15,950 | 6 | $0 (2022) |
| Servier Pharmaceuticals LLC | $9,201 | 22 | $0 (2020) |
| Genentech USA, Inc. | $4,506 | 5 | $0 (2019) |
| Merck Sharp & Dohme LLC | $3,600 | 9 | $0 (2024) |
| Incyte Corporation | $2,818 | 1 | $0 (2022) |
| Celgene Corporation | $1,000 | 1 | $0 (2023) |
| JAZZ PHARMACEUTICALS INC. | $411.13 | 4 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $103.85 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,076 | 5 | Merck Sharp & Dohme LLC ($875.00) |
| 2023 | $14,567 | 6 | Amgen Inc. ($12,863) |
| 2022 | $16,789 | 9 | SECURA BIO, INC. ($8,250) |
| 2021 | $29,715 | 9 | Secura Bio, Inc. ($18,315) |
| 2020 | $5,323 | 13 | Servier Pharmaceuticals LLC ($4,519) |
| 2019 | $15,667 | 25 | Amgen Inc. ($5,931) |
| 2018 | $23,441 | 17 | Amgen Inc. ($23,316) |
| 2017 | $16,768 | 17 | Amgen Inc. ($16,703) |
All Payment Transactions
101 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/07/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug), VYXEOS, Defitelio | Food and Beverage | In-kind items and services | $123.12 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/05/2024 | Amgen Inc. | Blincyto (Biological) | Food and Beverage | In-kind items and services | $63.24 | General |
| Category: Oncology | ||||||
| 09/12/2024 | Amgen Inc. | Blincyto (Biological) | Food and Beverage | In-kind items and services | $14.99 | General |
| Category: Oncology | ||||||
| 08/26/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $375.00 | General |
| 04/03/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 12/10/2023 | JAZZ PHARMACEUTICALS INC. | — | Food and Beverage | In-kind items and services | $147.01 | General |
| 11/17/2023 | Celgene Corporation | — | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,000.00 | General |
| 10/04/2023 | Amgen Inc. | LUMAKRAS (Drug) | Consulting Fee | Cash or cash equivalent | $12,862.50 | General |
| Category: Oncology | ||||||
| 08/29/2023 | Daiichi Sankyo Inc. | — | Food and Beverage | In-kind items and services | $22.86 | General |
| 07/30/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $35.10 | General |
| Category: Oncology | ||||||
| 03/29/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 12/10/2022 | Amgen Inc. | Blincyto (Biological) | Food and Beverage | In-kind items and services | $123.97 | General |
| Category: Oncology | ||||||
| 12/06/2022 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $2,818.00 | General |
| 11/23/2022 | Amgen Inc. | Kyprolis (Drug) | Food and Beverage | In-kind items and services | $21.84 | General |
| Category: Oncology | ||||||
| 10/25/2022 | SECURA BIO, INC. | COPIKTRA (Drug), COPIKTRA, COPIKTRA | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| Category: Hematology and Oncology | ||||||
| 06/16/2022 | SECURA BIO, INC. | COPIKTRA (Drug), COPIKTRA, COPIKTRA | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: Hematology and Oncology | ||||||
| 05/23/2022 | Amgen Inc. | Blincyto (Biological) | Food and Beverage | In-kind items and services | $75.00 | General |
| Category: Oncology | ||||||
| 04/25/2022 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 04/22/2022 | Kite Pharma, Inc. | Tecartus (Drug) | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| Category: CELLT | ||||||
| 02/24/2022 | SECURA BIO, INC. | COPIKTRA (Drug), COPIKTRA, COPIKTRA | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| Category: Hematology and Oncology | ||||||
| 12/03/2021 | Kite Pharma, Inc. | Tecartus (Drug) | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| Category: CELLT | ||||||
| 10/22/2021 | Secura Bio, Inc. | FARYDAK (Drug), COPIKTRA | Consulting Fee | Cash or cash equivalent | $9,562.50 | General |
| Category: ORAL ONCOLOGIC | ||||||
| 10/19/2021 | Kite Pharma, Inc. | Tecartus (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: CELLT | ||||||
| 10/15/2021 | Kite Pharma, Inc. | Tecartus (Drug) | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: CELLT | ||||||
| 08/16/2021 | Secura Bio, Inc. | FARYDAK (Drug), COPIKTRA | Consulting Fee | Cash or cash equivalent | $4,627.50 | General |
| Category: ORAL ONCOLOGIC | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 142 | 335 | $94,571 | $32,797 |
| 2022 | 6 | 159 | 383 | $102,470 | $36,567 |
| 2021 | 6 | 163 | 437 | $118,226 | $42,789 |
| 2020 | 6 | 169 | 526 | $134,893 | $45,438 |
Total Patients
633
Total Services
1,681
Medicare Billing
$157,591
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 30 | 151 | $36,344 | $15,022 | 41.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 25 | 56 | $20,576 | $6,722 | 32.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 40 | 68 | $17,324 | $5,230 | 30.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 20 | 25 | $10,900 | $3,533 | 32.4% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2023 | 14 | 18 | $6,828 | $1,155 | 16.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 13 | 17 | $2,599 | $1,134 | 43.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 33 | 173 | $38,752 | $14,789 | 38.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 43 | 97 | $30,458 | $11,158 | 36.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 22 | 26 | $11,336 | $4,362 | 38.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 30 | 51 | $11,883 | $4,097 | 34.5% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2022 | 17 | 21 | $7,896 | $1,245 | 15.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 14 | 15 | $2,145 | $914.71 | 42.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 46 | 147 | $46,158 | $16,652 | 36.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 34 | 186 | $41,664 | $16,439 | 39.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 22 | 22 | $9,592 | $3,773 | 39.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 30 | 44 | $10,252 | $3,527 | 34.4% |
| 38222 | Diagnostic aspirations and biopsies of bone marrow | Facility | 2021 | 15 | 22 | $8,272 | $1,408 | 17.0% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 16 | 16 | $2,288 | $991.84 | 43.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 37 | 205 | $45,920 | $18,594 | 40.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 59 | 161 | $50,554 | $13,547 | 26.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 17 | 89 | $13,884 | $5,603 | 40.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 23 | 30 | $13,080 | $5,290 | 40.4% |
| 38222 | Bone marrow biopsy and aspiration | Facility | 2020 | 17 | 24 | $9,024 | $1,319 | 14.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 16 | 17 | $2,431 | $1,085 | 44.6% |
About Ashkan Emadi, MD, PHD
Ashkan Emadi, MD, PHD is a Internal Medicine healthcare provider based in Morgantown, West Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/25/2007. The National Provider Identifier (NPI) number assigned to this provider is 1457562753.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Ashkan Emadi, MD, PHD has received a total of $123,347 in payments from pharmaceutical and medical device companies, with $1,076 received in 2024. These payments were reported across 101 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($113,621).
As a Medicare-enrolled provider, Emadi has provided services to 633 Medicare beneficiaries, totaling 1,681 services with total Medicare billing of $157,591. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology, Hematology & Oncology
- Location Morgantown, WV
- Active Since 05/25/2007
- Last Updated 04/05/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1457562753
Products in Payments
- Blincyto (Biological) $41,093
- FARYDAK (Drug) $18,315
- Tecartus (Drug) $15,950
- LUMAKRAS (Drug) $12,863
- COPIKTRA (Drug) $8,250
- ASPARLAS (Drug) $4,622
- ONCASPAR (Drug) $4,579
- VENCLEXTA (Biological) $4,506
- Kyprolis (Biological) $237.61
- Kyprolis (Drug) $165.03
- RYLAZE (Drug) $123.12
- COSENTYX (Biological) $103.85
- VYXEOS (Drug) $98.54
- Erwinaze (Drug) $42.46
- CALQUENCE (Drug) $35.10
- Evomela (Drug) $22.32
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Morgantown
Dr. Partho Sengupta, Md, Dm, MD, DM
Internal Medicine — Payments: $152,664
Internal Medicine $152,664
Dr. Latoya Linton-Frazier, Md, MD
Internal Medicine — Payments: $72,467
Internal Medicine $72,467
Ward Paine, Md, MD
Internal Medicine — Payments: $69,016
Internal Medicine $69,016
Dr. John Nasr, Md, MD
Internal Medicine — Payments: $35,066
Internal Medicine $35,066
Dr. Matthew Gaskill, D.o, D.O
Internal Medicine — Payments: $21,227
Internal Medicine $21,227
Dr. Ihtishaam Qazi, M.d, M.D
Internal Medicine — Payments: $13,090
Internal Medicine $13,090